Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience

Gilda Varricchi, Diego Bagnasco, Matteo Ferrando, Francesca Puggioni, Giovanni Passalacqua, Giorgio W. Canonica

Research output: Contribution to journalReview article

Abstract

Eosinophils represent approximately 1% of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the β common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Rα and a common subunit βc shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Rα compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5.

Original languageEnglish
Pages (from-to)40-45
Number of pages6
JournalTherapeutic Advances in Respiratory Disease
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Interleukin-5
Eosinophils
Asthma
Basophils
Interleukin-3
Interleukins
Granulocyte-Macrophage Colony-Stimulating Factor
Th2 Cells
Natural Killer T-Cells
Mast Cells
Leukocytes
Stem Cells
Bone Marrow
mepolizumab
Lymphocytes
Cytokines

Keywords

  • asthma
  • eosinophilia
  • exacerbations
  • IL-5
  • mepolizumab
  • personalized medicine
  • severe asthma
  • targeted therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this

Mepolizumab in the management of severe eosinophilic asthma in adults : Current evidence and practical experience. / Varricchi, Gilda; Bagnasco, Diego; Ferrando, Matteo; Puggioni, Francesca; Passalacqua, Giovanni; Canonica, Giorgio W.

In: Therapeutic Advances in Respiratory Disease, Vol. 11, No. 1, 01.01.2017, p. 40-45.

Research output: Contribution to journalReview article

Varricchi, Gilda ; Bagnasco, Diego ; Ferrando, Matteo ; Puggioni, Francesca ; Passalacqua, Giovanni ; Canonica, Giorgio W. / Mepolizumab in the management of severe eosinophilic asthma in adults : Current evidence and practical experience. In: Therapeutic Advances in Respiratory Disease. 2017 ; Vol. 11, No. 1. pp. 40-45.
@article{da3ce4b85ac148e1af9561840f52d637,
title = "Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience",
abstract = "Eosinophils represent approximately 1{\%} of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the β common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Rα and a common subunit βc shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Rα compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5.",
keywords = "asthma, eosinophilia, exacerbations, IL-5, mepolizumab, personalized medicine, severe asthma, targeted therapy",
author = "Gilda Varricchi and Diego Bagnasco and Matteo Ferrando and Francesca Puggioni and Giovanni Passalacqua and Canonica, {Giorgio W.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/1753465816673303",
language = "English",
volume = "11",
pages = "40--45",
journal = "Therapeutic Advances in Respiratory Disease",
issn = "1753-4658",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Mepolizumab in the management of severe eosinophilic asthma in adults

T2 - Current evidence and practical experience

AU - Varricchi, Gilda

AU - Bagnasco, Diego

AU - Ferrando, Matteo

AU - Puggioni, Francesca

AU - Passalacqua, Giovanni

AU - Canonica, Giorgio W.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Eosinophils represent approximately 1% of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the β common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Rα and a common subunit βc shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Rα compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5.

AB - Eosinophils represent approximately 1% of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the β common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Rα and a common subunit βc shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Rα compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5.

KW - asthma

KW - eosinophilia

KW - exacerbations

KW - IL-5

KW - mepolizumab

KW - personalized medicine

KW - severe asthma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85008490013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008490013&partnerID=8YFLogxK

U2 - 10.1177/1753465816673303

DO - 10.1177/1753465816673303

M3 - Review article

AN - SCOPUS:85008490013

VL - 11

SP - 40

EP - 45

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

SN - 1753-4658

IS - 1

ER -